Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia

Ivosidenib (AG-120) is an oral, targeted agent that suppresses production of the oncometabolite 2-hydroxyglutarate via inhibition of the mutant isocitrate dehydrogenase 1 (IDH1; mIDH1) enzyme. From a phase 1 study of 258 patients with IDH1-mutant hematologic malignancies, we report results for 34 pa...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Blood
Auteurs principaux: Roboz, Gail J., DiNardo, Courtney D., Stein, Eytan M., de Botton, Stéphane, Mims, Alice S., Prince, Gabrielle T., Altman, Jessica K., Arellano, Martha L., Donnellan, Will, Erba, Harry P., Mannis, Gabriel N., Pollyea, Daniel A., Stein, Anthony S., Uy, Geoffrey L., Watts, Justin M., Fathi, Amir T., Kantarjian, Hagop M., Tallman, Martin S., Choe, Sung, Dai, David, Fan, Bin, Wang, Hongfang, Zhang, Vickie, Yen, Katharine E., Kapsalis, Stephanie M., Hickman, Denice, Liu, Hua, Agresta, Samuel V., Wu, Bin, Attar, Eyal C., Stone, Richard M.
Format: Artigo
Langue:Inglês
Publié: American Society of Hematology 2020
Sujets:
Plenary Paper
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7019193/
https://ncbi.nlm.nih.gov/pubmed/31841594
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2019002140
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires